|
Volumn 338, Issue 6106, 2012, Pages 491-495
|
Glial progenitor cell - Based treatment and modeling of neurological disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALEMTUZUMAB;
FINGOLIMOD;
MYELIN;
NATALIZUMAB;
PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;
RITUXIMAB;
BRAIN;
COGNITION;
DISEASE TREATMENT;
MENTAL HEALTH;
NEUROLOGY;
PATHOGENICITY;
RODENT;
BRAIN STEM;
CANAVAN DISEASE;
CARCINOGENESIS;
CELL EXPANSION;
CELL FUNCTION;
CEREBELLUM;
CEREBRAL PALSY;
COGNITION;
CRANIAL NERVE;
DEMYELINATION;
EMBRYONIC STEM CELL;
ENGRAFTMENT;
ENZYME REPLACEMENT;
GANGLIOSIDOSIS;
GLIA CELL;
GLOBOID CELL LEUKODYSTROPHY;
GRAFT RECIPIENT;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
IN VIVO STUDY;
LEUKOMALACIA;
MACROGLIA;
METACHROMATIC LEUKODYSTROPHY;
MULTIPLE SCLEROSIS;
MYELINATION;
NERVE FIBER;
NERVE ROOT;
NEUROLOGIC DISEASE;
NEURONAL CEROID LIPOFUSCINOSIS;
NIEMANN PICK DISEASE;
NONHUMAN;
OLIGODENDROGLIA;
PATHOGENESIS;
PELIZAEUS MERZBACHER DISEASE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHENOTYPE;
PRIORITY JOURNAL;
REMYELINIZATION;
REVIEW;
SCHILDER DISEASE;
SPINAL CORD;
STEM CELL TRANSPLANTATION;
|
EID: 84867768901
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.1218071 Document Type: Review |
Times cited : (154)
|
References (54)
|